Cover Image

A molecular risk score integrating BAALC, ERG and WT1 expression levels for risk stratification in acute promyelocytic leukemia

To date risk stratification in acute promyelocytic leukemia (APL) is based on highly dynamic leukocyte and platelet counts only. To identify a more robust risk stratification model, a molecular risk score was developed based on expression levels of the genes BAALC, ERG and WT1. Hereby, the main focu...

Full description

Saved in:
Bibliographic Details
Main Authors: Hecht, Anna (Author) , Nowak, Daniel (Author) , Nowak, Verena (Author) , Hanfstein, Benjamin (Author) , Weiß, Christel (Author) , Hofmann, Wolf-Karsten (Author) , Lengfelder, Eva (Author) , Nolte, Florian (Author)
Format: Article (Journal)
Language:English
Published: November 2015
In: Leukemia research
Year: 2015, Volume: 39, Issue: 11, Pages: 1172-1177
ISSN:1873-5835
DOI:10.1016/j.leukres.2015.08.010
Online Access:Verlag, Volltext: http://dx.doi.org/10.1016/j.leukres.2015.08.010
Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S0145212615303635
Get full text
Author Notes:Anna Hecht, Daniel Nowak, Verena Nowak, Benjamin Hanfstein, Thomas Büchner, Karsten Spiekermann, Christel Weiß, Wolf-Karsten Hofmann, Eva Lengfelder, Florian Nolte
Description
Summary:To date risk stratification in acute promyelocytic leukemia (APL) is based on highly dynamic leukocyte and platelet counts only. To identify a more robust risk stratification model, a molecular risk score was developed based on expression levels of the genes BAALC, ERG and WT1. Hereby, the main focus was on prediction of relapse. The integrative risk score divided patients into two groups with highly significant differences in outcome. It discriminated a high risk group with a high incidence of relapse successfully from a low risk group with no APL-related events after achievement of first remission. Especially the concurrent presence of molecular risk factors showed to be a negative prognostic factor in APL. The molecular risk score might be a promising approach to guide monitoring of APL patients and therapeutic decisions in the future.
Item Description:Gesehen am 20.12.2017
Physical Description:Online Resource
ISSN:1873-5835
DOI:10.1016/j.leukres.2015.08.010

Similar Items